Skip to content

Acute Coronary Syndrome in Patients With COVID-19

How to Decide Which COVID-19 Patient With Myocardial Infarction to Send to the Cath Lab? - A Case Series of COVID-19 Patients With Myocardial Infarction

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05732597
Acronym
ACS-COVID
Enrollment
26
Registered
2023-02-17
Start date
2020-11-01
Completion date
2022-02-27
Last updated
2024-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, COVID-19, Myocardial Infarction, Myocardium; Injury

Keywords

COVID-19, Coronavirus, Acute coronary syndrome, Troponin

Brief summary

The aim of this study was to find a clinical or laboratory parameter, that would help in distinguishing between COVID-19 patients with myocardial infarction (MI), who have an infarct-related artery (IRA) and therefore, require immediate revascularization, and those, who have no IRA.

Detailed description

The coronavirus pandemic has hit the world with its vast contagiousness, high morbidity, and mortality Apart from the direct damage to the lung tissue, the corona virus infection is associated with multiple organ damage, including the heart. Emerging evidence reveals a direct correlation between COVID-19 and cardiovascular complications, such as heart failure, myocarditis, arrhythmias, conduction abnormalities and acute coronary syndromes. The SARS-CoV-2 infection can frequently induce coagulation abnormalities that are associated with cardiopulmonary deterioration and death as a possible complication in all patients, despite presence or absence of concomitant risk factors and diseases. In addition, many patients with severe COVID-19 undergo thromboembolic events, which seem to be related to this particular coagulopathy. One of the most unpleasant and life-threatening types of thromboembolism is the one involving the coronary circulation, thus causing a heart attack. Many additional problems arise due to this condition e.g., access to a Cath lab, exposure of additional medical personnel, more complications and increased mortality for the patients. Invasive angiography for COVID-19 patients is logistically challenging and, in some cases, there is no intervention target, since microcirculatory disease and thrombosis is common in this group. Therefore, the investigators studied in detail the case series of 10 patients referred for primary percutaneous coronary intervention (pPCI) for MI in our catheterization laboratory during the course of COVID-19 infection. And the investigators set themselves the purpose to evaluate if there are some factors or parameters that could predict the presence of an interventional target - infarct related artery (IRA), prior to catheterization, and to determine their sensitivity and specificity.

Interventions

PROCEDURECoronary angiography

A coronary angiogram is a procedure that uses X-ray imaging to see the patient's blood vessels of the heart. The test is generally done to see if there's a restriction in blood flow going to the heart.

Sponsors

Bulgarian Cardiac Institute
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Acute coronary syndrome (ACS) * COVID-19 infection

Exclusion criteria

* No combination of ACS and COVID-19 infection

Design outcomes

Primary

MeasureTime frame
to find a clinical or laboratory parameter, that would help in distinguishing between COVID-19 patients with MI and IRA and those, who have no IRADuring the whole study

Countries

Bulgaria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026